Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04306510 · ClinicalTrials.gov registry record · Phase 4
A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN
A Phase 4 study, sponsored by Akcea Therapeutics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT04306510 is a Phase 4 study that was terminated before completion, run by Akcea Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT04306510, a Phase 4 study, was terminated before completion, sponsored by Akcea Therapeutics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The objective of the study was to characterize adverse events (AEs) occurring within one day of TEGSEDI administration to adult participants with hATTR-PN overall and in individual participants with respect to time course of AE onset, vital sign changes, preventive measures, treatment required, risk factors, and subsequent adverse outcomes.
Interventions
- DRUG TEGSEDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-01-21 |
| Est. Completion | 2024-03-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04306510
The ClinicalTrials.gov registry entry for NCT04306510 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akcea Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TEGSEDI is the first listed.
NCT04306510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04306510 about?
NCT04306510 is a clinical study titled "A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN". The objective of the study was to characterize adverse events (AEs) occurring within one day of TEGSEDI administration to adult participants with hATTR-PN overall and in individual participants with respect to time course of AE onset, vital sign changes, preventive measures, treatment required, risk...
What is the current status of trial NCT04306510?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2021-01-21. Estimated completion is 2024-03-20.
What interventions are being tested in trial NCT04306510?
The interventions under investigation include: TEGSEDI (DRUG).
Who is sponsoring clinical trial NCT04306510?
This trial is sponsored by Akcea Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.